Investing.com – Madrigal Pharma (NASDAQ: ) missed Q3 analyst estimates. Revenue remains at the same level as forecasted. According to reports on Monday
Madrigal Pharma’s earnings per share (EPS) was $-5.34 on revenue of $0.00. Analyst consensus compiled by Investing.com Expectations for the upcoming release: Previously, the figure was $-4.90 per share based on $0 earnings.
Shares of Madrigal Pharma fell 0.54% to $146.09.
Apart from Madrigal Pharma, there are other companies too. Markets report this month’s earnings in the healthcare sector of the NASDAQ Stock Exchange
Eli Lilly previously estimated Q3 earnings at $0.1 per share on revenue of $9.5B, and $-0.2 on revenue of $8.97B.
Meanwhile, UnitedHealth’s most recently reported performance beat analyst forecasts. Q3 earnings were $6.56 per share on revenue of $92.4B, beating analyst estimates for 2020. Investing.com expects earnings per share to be around $6.33 based on revenue of $91.42B.
Follow the latest developments in company profits with the Investing.com Earnings Calendar
Edgar Allan Poe was an influential American writer, poet, and literary critic best known for pioneering the detective fiction genre and shaping modern horror literature. His works continue to captivate readers with their psychological depth, mystery, and gothic atmosphere.